Abstract:Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME, the immune checkpoints and immunosuppressive chemokines, and currently used inhibitors targeting these pathways. These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME: protein kinase C (PKC) signaling, Notch, and transforming growth factor (TGF-β) signaling, Endoplasmic Reticulum (ER) stress response, lactate signaling, Metabolic reprogramming, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and Siglec signaling pathways. We also discuss the recent advances in Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3) and Lymphocyte Activating Gene 3 (LAG3) immune checkpoint inhibitors along with the C-C chemokine receptor 4 (CCR4)- C-C class chemokines 22 (CCL22)/ and 17 (CCL17), C-C chemokine receptor type 2 (CCR2)- chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 5 (CCR5)- chemokine (C-C motif) ligand 3 (CCL3) chemokine signaling axis in the TME. In addition, this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME, which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies. We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response. Overall, this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME, highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology. We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors, such as the inhabitant human microbiome, which have the potential to modulate TME biology and drug responses.

Immunomodulation by endothelial cells: prospects for cancer therapy

Endothelial cells in tumor microenvironment: insights and perspectives

Single‐cell transcriptomics reveals antigen‐presenting capacity and therapeutic resistance potential of immunomodulatory endothelial cells in colorectal cancer

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors

Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy

Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics

Immunologic tumor microenvironment modulators for turning cold tumors hot

Unraveling the Tumor Microenvironment: Insights into Cancer Metastasis and Therapeutic Strategies

Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer

Tumor microenvironment signaling and therapeutics in cancer progression

Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers

Modelling the tumor immune microenvironment for precision immunotherapy

Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Modulation of T cell function and survival by the tumor microenvironment

Towards targeting the breast cancer immune microenvironment

Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies